Tangram Therapeutics, formerly e-therapeutics, has relaunched with a focus on RNA interference medicines. The company is advancing a pipeline of GalOmic medicines, with lead program TGM-312 for MASH approaching a CTA submission in Q4 2025. Tangram also introduced LLibra OS, a next-gen AI platform to accelerate target discovery and siRNA design. The company aims to combine AI, biology, and chemistry to develop differentiated RNAi medicines. Their unique approach is designed to reduce risk and speed up the development of innovative therapies. Tangram Therapeutics is committed to making smarter decisions earlier in drug development to benefit patients.

For more information, visit www.tangramtx.com. Press inquiries can be directed to [email protected], and for investor relations, contact [email protected].

Read more at GlobeNewswire: e-therapeutics Relaunches as Tangram Therapeutics and